Elena Verzoni

4.0k total citations
189 papers, 1.9k citations indexed

About

Elena Verzoni is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, Elena Verzoni has authored 189 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 164 papers in Pulmonary and Respiratory Medicine, 81 papers in Cancer Research and 79 papers in Oncology. Recurrent topics in Elena Verzoni's work include Renal cell carcinoma treatment (134 papers), Cancer Genomics and Diagnostics (73 papers) and Renal and related cancers (59 papers). Elena Verzoni is often cited by papers focused on Renal cell carcinoma treatment (134 papers), Cancer Genomics and Diagnostics (73 papers) and Renal and related cancers (59 papers). Elena Verzoni collaborates with scholars based in Italy, France and United States. Elena Verzoni's co-authors include Giuseppe Procopio, Filippo de Braud, Camillo Porta, Paolo Grassi, Emilio Bajetta, Mélanie Claps, Pierangela Sepe, Valentina Guadalupi, Alessia Mennitto and Bernard Escudier and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Lancet Oncology.

In The Last Decade

Elena Verzoni

175 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elena Verzoni Italy	22	1.3k	899	856	659	298	189	1.9k
Jiří Tomášek Czechia	16	834 0.6×	524 0.6×	680 0.8×	418 0.6×	177 0.6×	61	1.4k
Éric Dansin France	19	1.8k 1.3×	376 0.4×	1.4k 1.6×	330 0.5×	123 0.4×	113	2.4k
Bradley A. McGregor United States	27	1.4k 1.1×	782 0.9×	1.8k 2.1×	573 0.9×	155 0.5×	176	3.2k
Carol Peña France	7	875 0.7×	910 1.0×	765 0.9×	492 0.7×	154 0.5×	9	2.3k
Lionnel Geoffrois France	21	844 0.6×	504 0.6×	595 0.7×	268 0.4×	65 0.2×	90	1.6k
Jacques‐Olivier Bay France	6	1.5k 1.1×	1.1k 1.2×	751 0.9×	719 1.1×	68 0.2×	8	2.0k
Jong‐Mu Sun South Korea	25	1.1k 0.9×	528 0.6×	1.3k 1.5×	431 0.7×	120 0.4×	82	2.1k
Halla Nimeiri United States	26	386 0.3×	311 0.3×	1.2k 1.4×	239 0.4×	446 1.5×	84	1.8k
Holger Thurm United States	19	1.7k 1.3×	624 0.7×	1.4k 1.7×	470 0.7×	128 0.4×	48	2.2k
André P. Fay United States	22	1.4k 1.1×	674 0.7×	1.3k 1.5×	619 0.9×	102 0.3×	117	2.5k

Countries citing papers authored by Elena Verzoni

Since Specialization

Citations

This map shows the geographic impact of Elena Verzoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elena Verzoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elena Verzoni more than expected).

Fields of papers citing papers by Elena Verzoni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elena Verzoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elena Verzoni. The network helps show where Elena Verzoni may publish in the future.

Co-authorship network of co-authors of Elena Verzoni

This figure shows the co-authorship network connecting the top 25 collaborators of Elena Verzoni. A scholar is included among the top collaborators of Elena Verzoni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elena Verzoni. Elena Verzoni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stellato, Marco, Ernesto Zecca, Mélanie Claps, et al.. (2025). Medication-related jaw osteonecrosis in metastatic RCC treated with VEGFR-TKIs ± IO and bone agents: A real-world analysis. Tumori Journal. 111(5). 442–446.

Stellato, Marco, et al.. (2025). Pathological Complete Response in Metastatic Renal Cell Carcinoma Patients Treated With Cabozantinib Plus Nivolumab. Case Series and Literature Review. Clinical Genitourinary Cancer. 23(3). 102328–102328. 1 indexed citations

Miceli, Rosalba, Hanna Eriksson, Giuseppe Lo Russo, et al.. (2024). Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study. Acta Oncologica. 63. 213–219. 3 indexed citations

Beckermann, Kathryn E., Aviva G. Asnis-Alibozek, Michael B. Atkins, et al.. (2024). Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial. The Oncologist. 29(3). 254–262. 8 indexed citations

Guadalupi, Valentina, Elena Verzoni, Mélanie Claps, et al.. (2023). APPROACH trial: Multimodal approach in patients with mHSPC: A pragmatic, randomized, phase 3 trial of androgen-deprivation therapy (ADT) plus apalutamide (APA) versus ADT plus apalutamide (APA) and local treatment—Meet-URO 29 study.. Journal of Clinical Oncology. 41(16_suppl). TPS5115–TPS5115. 2 indexed citations

Tommasi, Chiara, Diana Giannarelli, Ugo De Giorgi, et al.. (2023). The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study. Therapeutic Advances in Urology. 15. 3633533712–3633533712. 3 indexed citations

Giannatempo, Patrizia, Valentina Guadalupi, Laura Marandino, et al.. (2023). Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy: Interim results from the phase 2 ARCADIA trial.. Journal of Clinical Oncology. 41(16_suppl). 4578–4578. 4 indexed citations

Maiorano, Brigida Anna, Ugo De Giorgi, Elena Verzoni, et al.. (2023). Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis. Targeted Oncology. 19(1). 1–11. 7 indexed citations

Zengin, Zeynep Büşra, Sumanta K. Pal, David F. McDermott, et al.. (2022). Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer. Clinical Genitourinary Cancer. 20(6). 553–557. 3 indexed citations

10.

Basso, Umberto, Giuseppe Procopio, Giuseppe Fornarini, et al.. (2021). Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16). Oncology. 99(12). 747–755. 2 indexed citations

11.

Mennitto, Alessia, Elena Verzoni, Francesco Cognetti, et al.. (2021). Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial. Expert Review of Clinical Pharmacology. 14(2). 261–268. 7 indexed citations

12.

Rinchai, Darawan, Elena Verzoni, Veronica Huber, et al.. (2021). Integrated transcriptional‐phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. SHILAP Revista de lepidopterología. 11(6). e434–e434. 5 indexed citations

13.

Velasco, Guillermo de, Òscar Reig, Francesco Massari, et al.. (2021). Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib. British Journal of Urology. 128(2). 254–261. 2 indexed citations

14.

Miceli, Rosalba, Hanna Eriksson, Alex J. Eustace, et al.. (2021). 1795P Gender difference in side effects of immunotherapy: A possible clue to optimize cancer treatment. Annals of Oncology. 32. S1223–S1224. 4 indexed citations

15.

Porta, Camillo, Elena Verzoni, Silvia Zai, et al.. (2020). Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial. Tumori Journal. 106(3). 257–266. 2 indexed citations

16.

Raimondi, Alessandra, Raffaele Ratta, Elena Verzoni, et al.. (2019). Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population. Clinical Genitourinary Cancer. 17(4). 291–298. 24 indexed citations

17.

Stanzi, Alessia, et al.. (2019). Post-surgical Regression of Thoracic Metastases After Salvage Lobectomy for Recurrent Renal Cell Carcinoma. Clinical Genitourinary Cancer. 18(3). e284–e288. 1 indexed citations

18.

Grassi, Paolo, Ludovic Doucet, Viktor Grünwald, et al.. (2017). Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents. Oncology. 92(5). 269–275. 3 indexed citations

19.

Verzoni, Elena, Agata Cova, Paola Squarcina, et al.. (2017). Broad immunomodulating effect of first-line Pazopanib in metastatic renal cell carcinoma patients. Annals of Oncology. 28. vi17–vi17. 1 indexed citations

20.

Procopio, Giuseppe, Elena Verzoni, Roberto Iacovelli, et al.. (2014). Time from Nephrectomy as a Prognostic Factor in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapies: Overall Results from a Large Cohort of Patients. Oncology. 88(3). 133–138. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact